A key factor in overcoming barriers to United States market entry is sharing the positive experiences of both healthcare professionals and patients, explained HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare during a presentation at SMi Biosimilars USA Conference in Iselin, NJ, that took place November 14-15, 2018.
A key factor in overcoming barriers to United States market entry is sharing the positive experiences of both healthcare professionals and patients, explained HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare during a presentation at SMi Biosimilars USA Conference in Iselin, NJ, that took place November 14-15, 2018.
In discussing the value of biosimilars to the healthcare system, Kim cited data from IMS Health that found that “biosimilars could lead to cumulative savings of up to $107 billion by 2020 in the United States and the top 5 European Union [EU] countries.” While the EU has been ahead of the curve when it comes to approving and prescribing biosimilars, the US market has been slower to generate uptake as the first product was approved some 10 years prior in the EU than in the United States.
Kim highlighted several challenges facing the US biosimilar market, such as physicians and patients alike lacking confidence in the products due to a “low level of education and awareness.” He discussed the results of 2 surveys that found that “67% of patients said they were ‘unaware’ of biosimilars,1 and when responding to the question ‘is a biosimilar safe?” 70% of patients said ‘no.’”2 In addition, he also mentioned the alleged “anti-biosimilar campaigns” that run in the United States as increasing the negative perception of biosimilars, as well as patent litigation that hinders biosimilars entering the market.
In discussing ways to address these market barriers, Kim emphasized that it’s not a task that can be accomplished by any one company alone. “In particular, it is important to highlight best practice[s] and work together to ensure as many patients as possible in the [United States] have access to treatment through the use of high quality, more cost-effective biosimilars,” he said.
When looking ahead to the future of the biosimilars market, Kim announced that Celltrion was looking forward to launching subcutaneous biosimilar infliximab next year. “We expect that this will generate further cost savings in addition to improved convenience as dual formulations would provide therapeutic approaches to optimize patient outcomes.”
References
1. Jacobs I, Singh E, Sewell KL, Al-sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross sectional survey. Patient Prefer Adherence. 2016;10:937-948.
2. Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33(12):2160-2172.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.